Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation

Research in Developmental Disabilities

Volumn 21, Issue 1, 2000, Pages 75-84

  Advokat, Claire D ^a   Mayville, Erik A ^a   Matson, Johnny L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; THIORIDAZINE;

ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DYSTONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MOTOR DYSFUNCTION; PARKINSONISM; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; HEALTH STATUS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED;

EID: 0034594481     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-4222(99)00031-1     Document Type: Article

References (18)

1. Baldessarini R.J. Drugs and the treatment of psychiatric disorders Psychosis and anxiety. Hardman J.G., Limbird L.E. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. 1996;McGraw-Hill, New York.
2. Borrison R.L. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol. 15[suppl 1]:1995;24S-29S.
3. Campbell M., Young P.I., Bateman D.N., Smith J.M., Thomas S.H.L. The use of atypical antipsychotics in the management of schizophrenia. J Clin Pharmacol. 47:1999;13-22.
4. Cohen S.A., Ihrig K., Lott R.S., Kerrick J.M. Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord. 28:1998;229-233.
5. Gualtieri C. The problem of tardive akathisia. Brain Cogn. 23:1993;102-109.
6. Hammock R.G., Schroeder S.S., Levine W.R. The effect of clozapine on self-injurious behavior. J Autism Dev Disord. 25:1995;611-626.
7. Hardan A., Johnson K., Johnson C., Hrecznyj B. Case study Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry. 35:1996;1551-1556.
8. Matson J.L., Baglio C.S. Administrator's Manual Matson Evaluation of Drug Side Effects (MEDS). 1998;Scientific Publishers, Inc, Baton Rouge, LA.
9. McDougle C.J., Brodkin E.S., Yeung P.P., Naylor S.T., Cohen D.J., Price L.H. Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol. 5:1995;273-282.
10. McKim W.A. Drugs and Behavior An Introduction to Behavioral Pharmacology. 3rd ed. 1996;Prentice Hall, Upper Saddle River, NJ.
11. Nicholson R., Awad G., Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry. 37:1998;372-376.
12. Pope H.G., Keek P.E., McElroy S.L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 143:1986;1227-1233.
13. Potenza M.N., McDougle C.J. Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs. 9:1998;213-232.
14. Rosebush P.I., Manzurek M.F. Neurological side effects of risperidone. Essential Psychopharmacol. 3:1999;43-64.
15. Sachdev P., Loneragan C. The present status of akathesia. J Nerv Ment Dis. 179:1991;381-391.
16. Thompson T.J., Berkson G. Stereotyped behavior of severely disabled children in classroom and free-play settings. Am J Ment Defic. 89:1985;580-586.
17. Vanden Borre R., Vermote R., Buttiens M., Thiry P., Dierick G., Geutjens J., Sieben G., Heylen S. Risperidone as add-on therapy in behavioural disturbances in mental retardation a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 87:1993;167-171.
18. Winslow R.S., Stiller V., Coons D.J., Robison M.W. Prevention of acute dystonic reactions in patients beginning high potency neuroleptics. Am J Psychiatry. 143:1986;706-710.